Nucleotide Synthesis Inhibition

Nucleotide synthesis inhibition blocks DNA or RNA building block formation preventing cell replication. Methotrexate inhibits dihydrofolate reductase halting nucleotide synthesis. Ribonucleotide reductase inhibitors reduce deoxyribonucleotide availability. Immunosuppression results from lymphocyte replication impairment. Cancer cell selectivity increases with targeting replication dependency.

Antimetabolite mechanisms exploit nucleotide synthesis dependency. Resistance mechanisms including enzyme upregulation warrant investigation. Therapeutic drug monitoring guides dose adjustments. Regulatory submissions address mechanism-of-action implications. Post-approval monitoring identifies unexpected effects.